Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in BRAF V600E Positive Erdheim Chester Disease
NCT02281760Phase 2Completed
- Sponsor
- National Human Genome Research Institute
- Start
- Nov 2014
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in Erdheim-Chester disease (ECD), sponsored by National Human Genome Research Institute. Primary endpoints: Number of Participants With Partial Response at 24 months, Number of Participants With Adverse Events at 24 months and 1 more. Started Nov 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on NCT02281760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281760.